Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 05 Jun 2019 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 24 Sep 2018 Status changed from not yet recruiting to recruiting.